Rep. Adam Schiff (D-Burbank) recently sent a letter to the Food and Drug Administration (FDA) urging the regulatory agency to address the recent price increase of epinephrine medication – also known as EpiPens – by the Mylan Corporation.
After a meeting with Elizabeth Isabella and her husband Ed, constituents who are parents of two children susceptible to anaphylaxis, Schiff witnessed first-hand the burden the drug price increase places on average families.
Schiff requested that the FDA prioritize the introduction of safe and affordable generic alternatives. EpiPens are sold in two-packs and cost approximately $600. The Mylan Corp. announced on Monday that it is offering a generic version of the EpiPen two-pack, which is priced at $300.
“The affordability of epinephrine injectors is critical to the health of Americans at risk of anaphylaxis. For families with high-deductible insurance plans, as well as those insured through Medicare, Medicaid, or the VA or without insurance at all, the out of pocket costs for the EpiPen has become cost-prohibitive,” Schiff said in the letter.
Elizabeth Isabella said affordable EpiPen pricing is crucial for families with children who need the medication.
“As the mother of two children with severe allergies requiring auto-injection epinephrine, every year I must purchase multiple boxes of EpiPens, sets for each child for school, home and after school activities,” Isabella said. “I am incredibly fortunate that my family has savings to pay for this life-preserving medication, though if the price continues to exponentially increase it will be difficult. I cannot imagine the fear and panic that parents who are not so fortunate are being forced to live with every day.”
This site uses Akismet to reduce spam. Learn how your comment data is processed.